Merck & Company, Inc. (MRK) Stock Price & How to Invest

Merck and Co., Inc. (NYSE: MRK) is a global research-intensive biopharmaceutical company headquartered in Rahway, New Jersey. It discovers, develops, manufactures, and markets prescription medicines, vaccines, and biologic therapies across oncology, infectious disease, cardiovascular, and diabetes, alongside a substantial Animal Health segment that sells vaccines and medicines for livestock and companion animals. The company operates under the MSD name outside the United States and Canada. Revenue flows primarily from pharmaceutical product sales, with oncology representing more than 60 percent of pharmaceutical revenue. Keytruda, a PD-1 inhibitor approved in more than 40 cancer indications, is the world's best-selling drug and the dominant revenue driver. Other meaningful contributors include the Gardasil HPV vaccine franchise, pulmonary arterial hypertension therapy Winrevair, pneumococcal vaccine Capvaxive, antiviral Lagevrio, and the Animal Health portfolio led by the Bravecto parasite treatment and Allflex livestock intelligence products.

Founded in 1891 as the U.S. subsidiary of the German chemical company E. Merck (now Merck KGaA, a legally separate company), Merck and Co. became fully independent after World War I, went public, and built its modern identity through decades of vaccine innovation and the mid-2010s discovery and commercialization of Keytruda. Robert M. Davis has served as chairman and chief executive officer since 2021, steering the company through Keytruda's commercial peak and into a strategic pivot toward pipeline diversification, including the acquisition of Prometheus Biosciences, Harpoon Therapeutics, and Verona Pharma, as well as a landmark partnership with Moderna on personalized mRNA cancer vaccines.

The central risk is Keytruda concentration: the drug accounts for roughly half of total company revenue, and its primary U.S. patents expire in late 2028, at which point biosimilars from companies including Celltrion and Samsung Bioepis are positioned to enter and compress pricing. This cliff is compounded by IRA Medicare price cuts already reducing Januvia reimbursement by 79 percent starting in 2026, creating a multi-billion-dollar annual headwind from drug pricing reform. Gardasil faces its own pressure from weak China demand and a CDC recommendation change that reduces the number of doses in the pediatric schedule, and near-term earnings growth is constrained by acquisition-related charges and tariff costs estimated at $200 million annually at current levels. The timing gap between Keytruda's revenue decline and the pipeline's commercial maturity, expected around the mid-2030s, is the key uncertainty investors must weigh.

26 analysts publish price targets on MRK, averaging $135.19 against a $130.20 price as of August 2026, or +3.8%. The published targets run from $105.00 to $155.00, a moderate spread, and the ratings split 19 buy, 8 hold, 1 sell. Over the last six months there have been 8 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MRK forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Merck & Company, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Keytruda's remaining runway is substantial. Keytruda recorded roughly $31.7 billion in sales in 2025, up 7 percent year over year, and management projects peak sales near $35 billion by 2028. The most optimistic published target, $155.00, assumes this works close to its best case.

The case against. The central risk is Keytruda concentration: the drug accounts for roughly half of total company revenue, and its primary U.S. The most pessimistic target, $105.00, is roughly what MRK is worth if this bites instead.

Read the full bull and bear case on MRK, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Merck & Company, Inc.'s investor relations page or your broker.

• Revenue (FY 2025): ~$65.0 billion
• Net Income (FY 2025): ~$18.3 billion
• Diluted EPS (FY 2025, GAAP): ~$7.28
• Gross Margin (FY 2025): ~74.8%
• P/E Ratio (TTM, as of June 25, 2026): ~34.9x
• Share Price (June 25, 2026): ~$123.91

Merck's trailing P/E of roughly 34.9x sits about 43 percent above its own 10-year median of 24.4x and above the drug manufacturers industry median of approximately 20.6x, reflecting a market that is pricing in continued Keytruda momentum and pipeline optionality rather than near-term earnings compression. The elevated multiple is somewhat counterintuitive given the 2028 patent cliff, but can be read as the market assigning value to the post-cliff pipeline and the subcutaneous Keytruda lifecycle extension. On an EPS-excluding-acquisition-charges basis, the stock's forward valuation looks more moderate, and GuruFocus rates MRK as fairly valued with a GF Value estimate of approximately $118.

If you want MRK exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses MRK naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to MRK: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MRK exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (HDV, XLV, VHT), which spreads the position across many companies. Or build it into a focused thematic portfolio, so MRK sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MRK fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Merck today is effectively a Keytruda-era cash machine in transition, generating roughly $65 billion in annual revenue with a gross margin near 75%, while racing to build a post-2028 revenue base across oncology, cardiovascular drugs, vaccines, and animal health. If you believe the company's more than 50 active clinical trials and its stated $70 billion pipeline opportunity can credibly bridge the Keytruda patent gap, the question becomes sizing and overlap, not timing. The risk is that biosimilar erosion of Keytruda after 2028 proves faster and deeper than the replacement pipeline can absorb, compounded by IRA-driven Medicare price cuts already in effect on legacy drugs like Januvia.

Whether MRK is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MRK a buy or a sell?, and where the stock could go from here in the MRK stock forecast.

For income investors, whether MRK pays a dividend and how the payout looks is covered in does MRK pay a dividend? And to weigh MRK against a peer, read the full side-by-side comparisons: MRK vs ABBV and MRK vs ABT.